TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27709308

Group type: EXPERIMENTAL
Intervention: Low-level laser acupuncture (12 sessions, 3 sessions/week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham laser acupuncture (12 sessions, 3 sessions/week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-level laser acupuncture
Number of subjects: 48
Study: 26069231

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0mg/kg/week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 4.0mg/kg/week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 24067320

Group type: EXPERIMENTAL
Intervention: Modulated light projections (specific colors and modulations in the frequency range of brainwaves)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo projection (nonmodulated white light)
Number of subjects: 117
Study: 21829202

Group type: EXPERIMENTAL
Intervention: GP's endorsement letter
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Enhanced procedural leaflet
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Both GP's letter and leaflet
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Electronic GP's signature on endorsement letter
Number of subjects: 1288
Study: 18180980

Group type: EXPERIMENTAL
Intervention: Active laser treatment (10.6 microm and 650 nm laser irradiation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser treatment (sham laser treatment)
Number of subjects: 40
Study: 17122208

Group type: EXPERIMENTAL
Intervention: i.v. amino acid infusion (4 kJ kg(‐1) h(‐1) starting 2 h before surgery)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: i.v. amino acid infusion
Number of subjects: 180

Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 180
Study: 15068108

Group type: EXPERIMENTAL
Intervention: Collagen membrane (COLL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collagen membrane + Demineralized freeze-dried bone allograft (COBA)
Number of subjects: 20
Study: 11332875

Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (100 mg) - Test formulation (Rimantadin Lachema)
Number of subjects: 24
Study: 9153484

Group type: EXPERIMENTAL
Intervention: Albendazole therapy for 1 week (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Albendazole therapy for 2 weeks (n = 25)
Number of subjects: 50
Study: 7968650

Group type: EXPERIMENTAL
Intervention: HRT (oral or transdermal)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HRT (transdermal)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HRT (oral)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reference group (untreated)
Number of subjects: 61
Study: 3478732

Group type: EXPERIMENTAL
Intervention: 5mg PGE2 slow release hydrogel pessary
Number of subjects: 24

Group type: COMPARATOR
Intervention: 3mg vaginal tablet (Upjohn)
Number of subjects: 24
Study: 30249307

Group type: EXPERIMENTAL
Intervention: 1 hour of continuous direct observation for hand hygiene opportunities (HHOs)
Number of subjects: 0
Study: 28288767

Group type: EXPERIMENTAL
Intervention: IVM oral paste (0.2 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IVM oral solution (0.2 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IVM IM solution (0.2 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 64
Study: 27366506

Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-flow CPAP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low-flow CPAP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Deep breathing exercises, respiratory physiotherapy and O2 therapy
Number of subjects: 80
Study: 23931729

Group type: EXPERIMENTAL
Intervention: Clinical Videoteleconferencing (CVT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person delivery
Number of subjects: 0
Study: 21128258

Group type: EXPERIMENTAL
Intervention: Abatacept 3 mg/kg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Abatacept 30/10 mg/kg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 18204336

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17036618

Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 100
Study: 12731691

Group type: EXPERIMENTAL
Intervention: Product A (without active ingredients)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Product B (with active ingredients)
Number of subjects: 76
Study: 10702816

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 10 days (Group A)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 5 days (Group A)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 5 days (Group B)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 2 days (Group B)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CVC dressing changes at longer intervals (10 days for Group A and 5 days for Group B)
Number of subjects: 399
Study: 8779383

Group type: EXPERIMENTAL
Intervention: Test device comprising a Tuohy needle and clamp weighing 75.02 g applied to five vein sites (dorsum of arm, dorsum of hand, cephalic, ventrum of arm, cubital fossa)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Pain expectations ranked by volunteers
Number of subjects: 167
Study: 1649838

Group type: EXPERIMENTAL
Intervention: Ovine CRH infusion (1 microgram/kg.h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 10
Study: 6304787

Group type: EXPERIMENTAL
Intervention: Rolipram (3 mg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30975204

Group type: EXPERIMENTAL
Intervention: Surface neuromuscular electrical stimulation (NMES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mastication apparatus (MA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mandibular advancement oral appliance (OAm) with embedded thermosensitive microchip
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mandibular advancement oral appliance (OAm)
Number of subjects: 30
Study: 29480527

Group type: EXPERIMENTAL
Intervention: Internet-based training with weekly phone calls (n=232)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Educational control group with general positive parenting advice and one 45-minute phone call (n=232)
Number of subjects: 464
Study: 27899456

Group type: EXPERIMENTAL
Intervention: Controlled smoked cannabis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Controlled vaporized cannabis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oral cannabis administration
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Inhalation routes (smoked and vaporized)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oral dosing
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined THC ≥5 μg/L plus THCCOOH/11‐hydroxy‐THC ratio <20 cutoff
Number of subjects: 126
Study: 24670413

Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II receptor blocker)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 22421246

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mid‐palmar mini incision
Number of subjects: 105

Group type: COMPARATOR
Intervention: Regular open incision
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 105
Study: 20065047

Group type: EXPERIMENTAL
Intervention: Amphotericin B daily regimen (1 mg kg(‐1) day(‐1) for 15 days)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Amphotericin B alternate day regimen (1 mg kg(‐1) on alternate days for 15 days)
Number of subjects: 605
Study: 18687174

Group type: EXPERIMENTAL
Intervention: HSH40
Number of subjects: 60

Group type: COMPARATOR
Intervention: NS
Number of subjects: 60

Group type: COMPARATOR
Intervention: HES
Number of subjects: 60
Study: 15763053

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) combined with Ginsenosides (GS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11926175

Group type: EXPERIMENTAL
Intervention: Routine care plus a detailed cognitive assessment (112 patients)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Routine care (116 patients)
Number of subjects: 228
Study: 10102070

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 145
Study: 7565822

Group type: EXPERIMENTAL
Intervention: Rectal solution of apomorphine (10 or 15 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gelatin suppository (25 and 50 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Witepsol‐H15 suppository (50 and 100 mg)
Number of subjects: 5
Study: 2225702

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg daily for 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Indomethacin, 50 mg twice a day
Number of subjects: 13
Study: 334221

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study: 30643982

Group type: EXPERIMENTAL
Intervention: SK-1202 (26 g/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: SK-1202 (39 g/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 28025352

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5 ml; 5 mg/ml)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 47
Study: 24211500

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study: 23743535

Group type: EXPERIMENTAL
Intervention: Loading (LD group) - 3 mandatory doses of intravitreal bevacizumab
Number of subjects: 99

Group type: COMPARATOR
Intervention: No Loading (NLD group) - no mandatory doses after baseline dose
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Loading (LD group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No Loading (NLD group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Loading (LD group) and No Loading (NLD group)
Number of subjects: 99
Study: 19934030

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1977
Study: 18940534

Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (10, 20, or 40 mg/day) for 6 weeks
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (40 mg/day) for 33 weeks
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (10 or 20 mg/day) for 53 weeks
Number of subjects: 248
Study: 16841664

Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (dipyridamole and benazepril)
Number of subjects: 67
Study: 12480116

Group type: EXPERIMENTAL
Intervention: Coaching by community pharmacists (3 drug coaching contacts and a 25-min take-home video)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 148
Study: 10912701

Group type: EXPERIMENTAL
Intervention: Rehabilitation (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abnormal control (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects (Group C)
Number of subjects: 0
Study: 1520059

Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Compression ultrasonography
Number of subjects: 83

Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 83
Study: 6418670

Group type: EXPERIMENTAL
Intervention: CMC‐containing artificial saliva (Group I, 40 patients)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Alternating CMC‐ and mucin‐containing artificial saliva (Group II, 61 patients)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mucin‐containing artificial saliva (Group III, 36 patients)
Number of subjects: 137
Study: 31296519

Group type: EXPERIMENTAL
Intervention: Medical oncologists (MO) recommending thromboprophylaxis (TP)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Patient factors (age, clinical setting, reason for admission, pre‐admission performance status, risk of bleeding)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Palliative care (PC) physicians recommending thromboprophylaxis (TP)
Number of subjects: 1097
Study: 31721495

Group type: EXPERIMENTAL
Intervention: Modified socket shield technique (SST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional immediate implant placement
Number of subjects: 24
Study: 29224641

Group type: EXPERIMENTAL
Intervention: Individualized feedback on adherence to prescribing evidence-based therapy for physicians; weekly home visits from community health workers for patients.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Regular updates on advances in HF management for physicians; monthly HF educational tip sheets for patients.
Number of subjects: 320
Study: 27435412

Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 796

Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 796
Study: 24558280

Group type: EXPERIMENTAL
Intervention: Amazing Self‐Care Race educational activity
Number of subjects: 86
Study: 22565162

Group type: COMPARATOR
Intervention: 4 l Golytely single‐dosed (Go‐Si)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 4 l Golytely split‐dosed (Go‐Sp)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 238 g MiraLAX in 64 oz of Gatorade single‐dosed (Mlax‐Si)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: MiraLAX/Gatorade split‐dosed (Mlax‐Sp)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: MiraLAX/Gatorade (Mlax)
Number of subjects: 222
Study: 20731983

Group type: EXPERIMENTAL
Intervention: Concordant heavy drinkers (wives)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Heavy drinking couples (either partner)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Wife as heavy drinker
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Husband as heavy drinker
Number of subjects: 251

Group type: COMPARATOR
Intervention: Concordant abstainers/light drinkers
Number of subjects: 251
Study: 17438555

Group type: EXPERIMENTAL
Intervention: Family-based group treatment (15 separate sessions for parents and children)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine counseling (two appointments for children)
Number of subjects: 70
Study: 15960271

Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg/ml with 6 microg/kg naloxone
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0.4 mg/ml morphine
Number of subjects: 59
Study: 11922881

Group type: EXPERIMENTAL
Intervention: Indoleamine (via tryptophan depletion) plus catecholamine (via alpha‐methyl‐paratyrosine administration) depletion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indoleamine plus sham (via diphenhydramine administration) catecholamine depletion
Number of subjects: 10
Study: 9704689

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril (2.5 to 20 mg/day)
Number of subjects: 29
Study: 7653083

Group type: EXPERIMENTAL
Intervention: New compression device
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional method (manual compression and pressure dressing)
Number of subjects: 133
Study: 1758748

Group type: EXPERIMENTAL
Intervention: Nasal CPAP at levels of 0, 3, 5, and 8 cm H2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline (without CPAP support)
Number of subjects: 10
Study: 6758832

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral terbutaline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral salbutamol
Number of subjects: 11
Study: 31307850

Group type: EXPERIMENTAL
Intervention: Hybrid surgically assisted rapid maxillary expansion (SARME)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tooth-borne (TB) surgically assisted rapid maxillary expansion (SARME)
Number of subjects: 20
Study: 28888516

Group type: EXPERIMENTAL
Intervention: Animal-assisted activities (AAA) for 10 minutes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition (no AAA)
Number of subjects: 48
Study: 26349548

Group type: EXPERIMENTAL
Intervention: Concomitant administration of RV1 and OPV (monovalent, bivalent, or trivalent)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Staggered administration of RV1 and OPV (≥1 day apart)
Number of subjects: 409
Study: 23349519

Group type: EXPERIMENTAL
Intervention: Levodopa (6.65 ± 1.66 mg/kg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22548929

Group type: EXPERIMENTAL
Intervention: 3 T magnetic resonance angiography (MRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 T magnetic resonance angiography (MRA)
Number of subjects: 0
Study: 20428633

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 0g/2g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 3h
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 3h
Number of subjects: 4
Study: 17522235

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal and polychemotherapy therapy
Number of subjects: 0
Study: 15203440

Group type: EXPERIMENTAL
Intervention: 1.7 g naltrexone implant
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3.4 g naltrexone implant
Number of subjects: 34
Study: 12376047

Group type: EXPERIMENTAL
Intervention: Laser light treatment (wavelength 810 nm, dose 4 J/cm2) in Group A
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment (quasi-laser therapy) in Group B
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 65
Study: 9807612

Group type: EXPERIMENTAL
Intervention: Komesaroff vaporizer at dial positions 1 or 1.5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional vaporizer outside the circle for the first 10 minutes
Number of subjects: 0
Study: 7570843

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Aminosidine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (after aminosidine)
Number of subjects: 13
Study: 1971199

Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 IV lidocaine administered 1-4 minutes before intubation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 125
Study: 6771829

Group type: EXPERIMENTAL
Intervention: 5 mg methylphenidate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30910480

Group type: EXPERIMENTAL
Intervention: Pinning on paraffin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Direct fixation in formalin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cassette technique
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: No handling method
Number of subjects: 126
Study: 27561944

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study: 26649538

Group type: EXPERIMENTAL
Intervention: Online rehabilitation with professional guidance by an audiologist
Number of subjects: 0
Study: 24034834

Group type: EXPERIMENTAL
Intervention: 16 G biopsy needles (Group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 18 G biopsy needles (Group B)
Number of subjects: 88
Study: 21357882

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (CBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 81
Study: 19662024

Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-adrenergic agonist)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16508761

Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 18
Study: 15096075

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specifically olanzapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 11798851

Group type: EXPERIMENTAL
Intervention: Domestic piperacillin/tazobactam
Number of subjects: 63

Group type: COMPARATOR
Intervention: Timentin (Control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Opening group (Domestic piperacillin/tazobactam)
Number of subjects: 63
Study: 9726128

Group type: EXPERIMENTAL
Intervention: Home-based resistance training program
Number of subjects: 102
Study: 8308975

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser with shorter pulse duration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulsed dye laser with longer pulse duration
Number of subjects: 20
Study: 2508049

Group type: EXPERIMENTAL
Intervention: piperacillin, 300 mg/kg/day plus tobramycin, 10 and more mg/kg/day for 14 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: ceftazidime, 150 mg/kg/day for 14 days
Number of subjects: 21
Study: 1260780

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 40
Study: 30778821

Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 30851032

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-based biolimus-eluting stents (BES)
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1157